Dr. Philip B. Adamson will join as Chief Medical OfficerBonnie Handke will join as Senior Vice President of Patient Access, Reimbursement, and Healthcare EconomicsJennifer E. Englund joins as Senior Vice President of Global Clinical Affairs MINNEAPOLIS, May 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced three additions to its senior leadership team. Philip B. Adamson, MD, MSc, FACC, FESC, FRCP (Ed) has been appointed as Chief Medica ...

Dr. Philip B. Adamson will join as Chief Medical Officer Bonnie Handke will join as Senior Vice President of Patient Access, Reimbursement, and Healthcare Economics Jennifer E. Englund joins as Senior Vice President of Global Clinical Affairs MINNEAPOLIS, May 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced three additions to its senior leadership team. Philip B. Adamson, MD, MSc, FACC, FESC, FRCP (Ed) has been appointed as Chief Med ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40545 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 41-1983744 (State or other j ...

ATLANTA, May 01, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether CVRx, Inc. ("CVRx" or the "Company") (NASDAQ:CVRX) complied with federal securities laws. On April 30, 2024, CVRx announced its financial and operating results for the first quarter of 2024, noting the "lower than anticipated revenue was due primarily to the performance of our U.S. Heart Failure business, where there was some disruption within our sales organization at the time of the CEO transition, which led to decreas ...

CVRx (NASDAQ:CVRX) stock is falling hard on Wednesday after posting results from its earnings report for the first quarter of 2024.The bad news for investors in CVRX stock starts with its earnings per share of 0$1.04. That’s much worse than the -54 cents per share Wall Street was expecting. It’s also wider than the -55 cents per share from the same period of the year prior.Adding to this is CVRx’s revenue of $10.77 million. That’s another miss next to analysts’ estimate of $11.37 million for the quarter. Ho ...

财务数据和关键指标变化 - 第一季度总收入为10.8亿美元,同比增长35% [7][28] - 美国心力衰竭业务收入为9.7亿美元,同比增长42% [29] - 美国活跃植入中心数量从上年同期的122家增加到190家 [30] - 美国销售区域数量从上年同期的29个增加到39个 [30] - 欧洲收入为0.9亿美元,同比下降10% [30] - 欧洲活跃植入中心数量保持在6个 [30] - 毛利率从上年同期的83%上升到85% [31] 各条业务线数据和关键指标变化 - 美国心力衰竭业务收入增长,主要由于进入新销售区域、新客户以及医生和患者对Barostim的认知度提高 [29] - 欧洲收入下降10%,主要由于收入单元从52个下降到44个 [30] 各个市场数据和关键指标变化 - 美国市场收入增长42%,欧洲市场收入下降10% [29][30] 公司战略和发展方向 - 公司正在采取措施提高对Barostim疗法的认知度、增强临床证据、加强患者获取 [16][17][18][19][20][21] - 公司正在招聘首席医疗官、临床事务高级副总裁和患者获取高级副总裁等关键角色 [19][20][21] - 公司将暂停BATwire试验的入组,但将继续跟踪已入组患者 [24] - 公司将审查研发和临床组合,集中投资于少数高影响力项目 [23] 管理层对经营环境和未来前景的评论 - 公司CEO认为Barostim是一种非常有效且高度影响力的心力衰竭治疗方法,公司只触及了潜在患者群体的2% [11][13] - 公司CEO认为需要更好地支持现有的HFpEF适应症商业化努力 [12][13] - 公司CEO对公司的技术和市场机会以及组织的实力感到非常乐观 [25] - 公司预计2024年全年收入为50-53亿美元,毛利率为83%-85%,营业费用为92-98亿美元 [37] 问答环节重要的提问和回答 问题1 **Lilia-Celine Lozada 提问** 销售团队变动对业务的具体影响,以及公司下调全年指引的原因 [45][46][47][48][49][50][51][52][53] **Kevin Hykes 和 Jared Oasheim 回答** - 第一季度出现较高的销售人员流失,导致销售工作受到干扰 [46][47][48] - 这主要是由于CEO换届、新的销售补偿计划以及第一季度通常是销售人员换岗的高峰期等因素造成的 [46][47][48] - 公司采取了一系列措施来稳定销售团队,包括调整补偿计划和调整销售主管 [46][48][49] - 下调全年指引主要是由于第一季度无法如预期增加新的销售区域和活跃植入中心,导致全年基数较低 [49][50][51][52][53] 问题2 **Phillip Dantoin 提问** 公司对2024年下半年的销售增长有何信心 [56][57][58][59][60] **Jared Oasheim 回答** - 公司预计2024年下半年能够继续增加销售区域,恢复到每季度新增3个的水平 [57][58][59] - 公司相信通过培训新销售人员并重新介绍到现有活跃植入中心,能够提高整体销售业绩 [57][58][59][60] 问题3 **Margaret Kaczor 提问** 公司新增高管职位的具体计划和预期影响 [80][81][82][83][84][85][86][87][88][89] **Kevin Hykes 回答** - 公司已经在过去几天内成功聘请了临床事务、患者获取和医疗等关键高管角色 [80][81] - 这些新高管的加入将立即带来影响,帮助公司提高疗法认知度、增强临床证据、加强患者获取 [82][83][84][85][86][87][88][89] - 公司将更多关注现有HFpEF适应症的市场开发,而不是过度关注适应症扩展 [84][85][86][87]

Exhibit 99.1 CVRx Reports First Quarter 2024 Financial and Operating Results MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2024. Recent Highlights · Total revenue for the first quarter 2024 was $10.8 million, an increa ...

CVRx, Inc. (CVRX) recently announced the availability of additional data supporting the long-term benefits of Barostim. This includes the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure. These data highlight the long-term sustained benefits of Barostim in heart failure (HF) patients with reduced ejection fraction.It should be noted that BeAT-HF is a multi-center, prospective, randomized, controlled trial that began in April 2016 to develop scient ...

公司信息 - CVRx公司计划在2024年4月30日收盘后发布2024年第一季度财务和运营结果[1] - CVRx公司将在当天下午5:00举行电话会议，回顾其结果[1] - CVRx公司是一家专注于为心血管疾病患者开发、制造和商业化创新神经调节解决方案的商业阶段医疗器械公司[3] Barostim™ - Barostim™是FDA批准使用神经调节改善心力衰竭患者症状的第一种医疗技术[3] - Barostim是一种可植入设备，向颈动脉壁中的压力感受器传递电脉冲，旨在恢复自主神经系统的平衡，从而减轻心力衰竭症状[3] - Barostim已获得FDA突破性设备认定，并获得美国心力衰竭患者使用的FDA批准，同时在欧洲经济区获得了心力衰竭和难治性高血压的CE标志[3] - 欲了解更多关于Barostim的信息，请访问www.cvrx.com[3]

CVRx公司财务和运营结果发布 - CVRx公司计划在2024年4月30日收盘后发布2024年第一季度财务和运营结果[1] - CVRx公司将于当天下午5:00举行电话会议以审查其结果[1] CVRx公司背景介绍 - CVRx是一家专注于为心血管疾病患者开发、制造和商业化创新神经调节解决方案的商业化阶段医疗器械公司[3] Barostim神经调节技术 - Barostim是FDA批准使用神经调节改善心力衰竭患者症状的第一种医疗技术[3] - Barostim是一种可植入设备，向颈动脉壁中的压力感受器传递电脉冲，旨在恢复自主神经系统的平衡，从而减轻心力衰竭症状[3]